| Document |
Document Title |
|
JPH0745504B2 |
10-substituted-5,9-dioxatricyclo[6.4.0.0<2><,><6>] dodecane-4-one represented by following formula: wherein R1 is a hydrocarbon group, and R2 is a saturated or unsaturated hydrocarbon group, which may contain one or more substituents(s),...
|
|
JPH0739369B2 |
The phenylalkan(en)oic acids of the formula: wherein the substituants are defined as in the disclosure, possess an antagonism on leukotriene B4, and therefore, are useful for the prevention and treatment of several diseases induced by le...
|
|
JPH0739343B2 |
|
|
JPH0739344B2 |
|
|
JPH07109254A |
PURPOSE: To provide a lyophilized injection pharmaceutical containing PGE1 preservable at room temperature for a long period of time (for two years or longer). CONSTITUTION: PGE1 α-cyclodextrin and dextran 40 are dissolved in water foll...
|
|
JPH0723336B2 |
Carbacyclin derivatives of Formula I (I) wherein R1 is OR2 wherein R2 is hydrogen, C1-C10-alkyl, C3-C10-cycloalkyl, C6-C10-aryl, or a heterocyclic residue, or R1 is R3 wherein R3 is C1-C10-alkyl, C3-C10-cycloalkyl, C6-C10-aryl, C7-C14-ar...
|
|
JPH0770054A |
PURPOSE: To obtain a medicinal preparation which includes 15-dehydroxy- prostaglandin as an active ingredient and is useful as an allergic disease-treating agent, inflammatory disease-treating agent, antihistamic agent and a bronchodilat...
|
|
JPH0761965A |
PURPOSE: To produce a new compound low in stimulation to the eye, having a satisfactory intraoculara pressure reducing effect in a low concentration and useful for prevention and therapy of glaucoma. CONSTITUTION: A compound of formula I...
|
|
JPH0717562B2 |
The compound 1 5-cyclohexyl-9-deoxy- 13, 14-dihydro-2 min ,9 alpha -methano-3-oxa-4,5,6,16,17,18,19,20-octanor-3,7-(1 min ,3-in terphenylene)PGF1 and pharmacologically acceptable salts thereof.
|
|
JPH0717597B2 |
This invention relates to a process for making a compound of formula Iin the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy l...
|
|
JPH0753382A |
PURPOSE: To provide a monocyte swarmer factor gene manifestation inducer useful for preventing and treating e.g., atheromatous arteriosclerosis where accumulation of blood monocytes on foci is recognized, containing, as the active ingred...
|
|
JPH0714893B2 |
|
|
JPH0748345A |
PURPOSE: To obtain a new fluorine-containing prostaglandin analog having excellent safety and durability of activity, useful as a prodrug of PGE0 and converted to the corresponding PGE0 by the hydrolysis in the body to exhibit bio-activi...
|
|
JPH0748344A |
PURPOSE: To obtain a new prostaglandin analog having suppressed chemical instability while keeping high physiological activity of prostaglandin. CONSTITUTION: A prostaglandin analog expressed by the formula I [R1 is residue obtained by r...
|
|
JPH0733719A |
PURPOSE: To provide a novel compound which, when administered to warm- blooded animals, induces a bio-affecting response characteristic of the original acid from which the compound is derived and is less irritating and more excellent in ...
|
|
JPH078815B2 |
The present invention provides an optically active 2-methylenecyclopentanone derivative represented by the general formula (IX) (wherein R1 is a protective group for hydroxyl, and the symbol * represents an asymmetric carbon atom).
|
|
JPH075494B2 |
Prostaglandin derivatives, and specifically derivatives of isocarbacyclin, have an optionally substituted methylene group as a substituent on the alpha -carbon atom of the alpha -side chain. They have a variety of physiological effects, ...
|
|
JPH072711B2 |
|
|
JPH0710833A |
PURPOSE: To obtain a prostaglandin analogue excellent in stability and useful as a platelet agglutination inhibitor, a blood flow increasing agent and a hypotensive agent, and its fat emulsion. CONSTITUTION: This prostaglandin analogue i...
|
|
JPH0692361B2 |
Prostaglandin intermediates of the formula in which Z represents <2bL>C=O or R<1>, together with the oxygen atom to which it is bonded, represents a hydrolysable ester group, R, together with the oxygen atom to which it is bonded, repres...
|
|
JPH0692362B2 |
11-Haloprostane derivatives of general formula I (I) wherein X is F, Cl or Br, R1 is the residue CH2OH or wherein R2 means a hydrogen atom, an alkyl, cycloalkyl, aryl, phenacyl or heterocyclic residue, A is a -CH2-CH2- or cis-CH=CH-group...
|
|
JPH0692305B2 |
|
|
JPH06316525A |
PURPOSE: To provide a topical eye lotion compsn. for treating glaucoma and ocular hypertension which eliminates or decreases side effects while maintaining the effect of lowering the intraocular pressure. CONSTITUTION: The topical eye lo...
|
|
JPH0688966B2 |
|
|
JPH0681728B2 |
|
|
JPH06509110A |
The invention is related to the field of treating gastric and duodenal disorders and more specifically to the use of certain 13,14-dihydro-prostaglandin E derivatives, especially of PGE2, which are modified to contain a ring structure in...
|
|
JPH06509068A |
This invention provides novel compounds used in a method of determining platelet deposition. These compounds include 123I-SAP and analogues. Also provided is a method of determining platelet deposition in a subject comprising binding an ...
|
|
JPH0680027B2 |
PCT No. PCT/JP86/00486 Sec. 371 Date May 18, 1987 Sec. 102(e) Date May 18, 1987 PCT Filed Sep. 18, 1986 PCT Pub. No. WO87/01696 PCT Pub. Date Mar. 26, 1987.This invention relates to a novel prostacyclin represented by the formula: (I) [w...
|
|
JPH06263722A |
PURPOSE: To readily and efficiently obtain 7-substituted prostaglandins by subjecting aldehydes which are new intermediates to addition reaction with acetylenes and binding an α-chain having a cycloalkylene group thereto. CONSTITUTION: ...
|
|
JPH06507897A |
The present invention relates to 2-decarboxyl-2-acylthioalkyl prostaglandins that are potent ocular hypotentives, and are particularly suitable for the management of glaucoma.
|
|
JPH0667900B2 |
The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inh...
|
|
JPH0662559B2 |
|
|
JPH06227985A |
PURPOSE: To provide a method for administering prostaglandin to a patient liable to suffer from cartilage injury or chondrogenesis-inhibitory desease to inhibit cartilage injury. CONSTITUTION: An effective amount of this prostaglandin re...
|
|
JPH06220011A |
PURPOSE: To provide a new compound having intraocular tension-reducing activity, useful for the prevention and/or treatment of glaucoma. CONSTITUTION: The objective compound, 13,14-dihydro-9-epi-prostaglandin D2 isopropyl ester of formul...
|
|
JPH0655716B2 |
|
|
JPH0655736B2 |
|
|
JPH0655715B2 |
|
|
JPH06506439A |
PCT No. PCT/DE91/00925 Sec. 371 Date Dec. 14, 1994 Sec. 102(e) Date Dec. 14, 1994 PCT Filed Nov. 23, 1991 PCT Pub. No. WO92/09573 PCT Pub. Date Jun. 11, 1992The invention relates to cyclopentane ether derivatives of Formula I (I) their s...
|
|
JPH06199779A |
PURPOSE: To obtain the subject new compound which has an utero-contraction activity for delivery induction and a short active period. CONSTITUTION: An alkyl ester of trans-Δ2-15-deoxy-16-hydroxy-16-methyl-PGE1 of formula I (R is prefera...
|
|
JPH0651676B2 |
|
|
JPH06505506A |
PCT No. PCT/DE92/00865 Sec. 371 Date Jun. 11, 1993 Sec. 102(e) Date Jun. 11, 1993 PCT Filed Oct. 9, 1992 PCT Pub. No. WO93/07118 PCT Pub. Date Apr. 15, 1993.The invention relates to 9-substituted bicyclo[3.3.0]octane derivatives of formu...
|
|
JPH0643413B2 |
Compounds of the formula I are disclosed wherein R1 stands for hydrogen, C1-4 straight or branched alkyl or pharmacologically acceptable cation, R2 stands for hydrogen, C1-4 alkanoyl, benzoyl, or benzoyl substituted by C1-4 alkyl or halo...
|
|
JPH0641431B2 |
NEW MATERIAL:A compound shown by the formula I [R<1> is 1-10C (substituted) phenyl; Ar is 6-12C (substituted)phenyl; wavy line is single bond and E-form or Z-form based on double bond or a mixture of them]. EXAMPLE:4-p-Fluorophenylmethyl...
|
|
JPH06145085A |
PURPOSE: To provide the new compounds useful as an anti-thrombus agent, an anti-ulcer agent and an anti-tumor agent. CONSTITUTION: The compounds of the formula I or their salts, e.g. 2- decarboxy-2-hydroxymethyl-9β-methyl-carbacyclin. T...
|
|
JPH0635431B2 |
This invention relates to a process for making a compound of formula Iin the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy l...
|
|
JPH06107626A |
PURPOSE: To obtain a new prostaglandin derivative having excellent platelet aggregation suppressing action, more excellent pharmacodynamic effects than conventional prostaglandin and good long acting properties and reduced in side effect...
|
|
JPH06503345A |
The invention relates to homo-prostaglandin derivatives. More particularly, the present invention concerns 1a-homo derivatives of naturally occurring and synthetic prostaglandins, the corresponding bis- and trishomo-prostaglandin compoun...
|
|
JPH06100529A |
PURPOSE: To provide PGF2β isopropyl ester low in irritation to the eye, exhibiting a sufficient effect on lowering of intracular pressure in a low concentration and useful as a medicine for preventing and/or improving glaucoma. CONSTITU...
|
|
JPH06502390A |
The invention relates to cyclopentane derivatives of formula (I) and their salts with physiologically tolerables bases and the $g(a), $g(b) or $g(g)-cyclodextrin clathrates and the liposome-encapsulated compounds of formula (I), a proces...
|
|
JPH0617331B2 |
|
